| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514419000 | C=X bonded directly or indirectly by an acyclic carbon or carbon chain to ring carbon of the five-membered hetero ring (e.g., tryptophan, etc.) (X is chalcogen) | 84 |
| 20110196013 | Animal feed composition - The present invention relates to an animal feed composition that comprises free indole acetic acid (free IAA) or a derivative thereof. The invention also relates to a method for enhancing animal growth by feeding the animal with a composition according to the invention. The invention also relates to the use of free IAA or a derivative thereof in a method of therapy of animals in need of a growth-promoting treatment, such as immunocompromised animals, animals with a growth deficit or slow growing animals. The invention also relates to the use of free IAA or a derivative thereof for the preparation of a therapeutical composition for increasing the growth rate and/or the feed conversion rate and/or the immunity of animals in need of such a treatment, in particular immunocompromised or slow growing animals. A composition according to the invention may preferably be in the form of a food or feed supplement. | 08-11-2011 |
| 20100076052 | PERINDOPRIL FORMULATIONS - Pharmaceutical formulations comprising perindopril or its salts, isomers, enantiomers, polymorphs, metabolites, solvates, hydrates, and mixtures thereof, and at least one surface stabilizer. Also disclosed are methods of stabilizing perindopril in the formulations, and polyoxyethylene-polyoxypropylene block copolymers as surface stabilizers. | 03-25-2010 |
| 20080221198 | Novel Crystalline Forms of Antidiabetic Compounds - Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases. | 09-11-2008 |
| 20100004309 | Dietary Compositions and Methods for Protection Against Chemotherapy, Radiotherapy, Oxidative Stress, and Aging - The present invention relates to dietary compositions comprising reduced level of methionine, tryptophan, all amino acids, or protein, dietary compositions comprising glycerol as a substitute for monosaccharides, disaccharides, and polysaccharides, and hypocaloric or calorie free diets with reduced level of energy, carbohydrates, or protein. Also disclosed are methods of using these compositions and diets, as well as fasting, to protect subjects against chemotherapy, radiotherapy, oxidative stress, or aging. | 01-07-2010 |
| 20080293803 | MELATONIN DAILY DOSAGE UNITS - The present invention relates to a disposable container for a medicament or cosmetic agent for topical application, containing a single dose of melatonin or of a melatonin derivative which corresponds to a locally effective dose but which does not cause any systemic effect. | 11-27-2008 |
| 20080293802 | Chemical Compounds - The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I). | 11-27-2008 |
| 20120289574 | HYDRATE CRYSTALS - New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal are useful as sweeteners and for the preparation of orally consumed products, such as foods, beverages, pharmaceutical products, topical pharmaceutical products, and feeds containing general-purpose, stable, and safe monatin sodium salt crystals. | 11-15-2012 |
| 20110288145 | Novel Formulation For L-Tryptophane Comprising Carbidopa/Benserazide - The present invention relates to the use of L-tryptophan and a peripheral degradation inhibitor of L-tryptophan for the manufacture of a medicament for prevention or therapy of pain, depressions, sleeping disorders and other serotonin dependent diseases of the CNS, wherein L-tryptophan is present in a retarded and the peripheral degradation inhibitor is present in a non-retarded formulation. | 11-24-2011 |
| 20100261774 | Methods for the modulation of Leishmania major infection in mammals - Embodiments of the invention include methods for treating an infection of a mammal by an organism, such as | 10-14-2010 |
| 20090124682 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity - A compound of the formula (1) or a pharmaceutically-acceptable salt: (A chemical formula should be inserted here—please see paper copy enclosed herewith) (1) possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described. | 05-14-2009 |
| 20100249204 | CALCIUM SALTS OF INDOLE DERIVED STATINS - The present invention provides calcium salts of indole derived statins of the formula | 09-30-2010 |
| 20090306171 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS - Indole and indole-related compounds according to the formula (I) or (II) optionally having additional heteroatoms, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. Formula (I), formula (II). R | 12-10-2009 |
| 20100120887 | SUSTAINED RELEASE FORMULATION OF MELATONIN - The present invention relates to low-dose formulations of melatonin, and methods of use thereof, which provide a sustained release of melatonin so as to rapidly increase plasma levels of melatonin, maintain a relatively high level (which mimics the endogenous level of a young subject) for approximately 5-6 hours, and then decrease so as to achieve low levels by early morning (rapid washout), thereby avoiding a “hangover effect”. The sustained release formulations of the invention may be used to treat a variety of sleep-related disorders, including, but not limited to, delayed onset and maintenance forms of insomnia. | 05-13-2010 |
| 20090062369 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS - Administration of sPLA | 03-05-2009 |
| 20100280092 | N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS - This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 11-04-2010 |
| 20100137400 | PHARMACEUTICAL FORMULATION CONTAINING AN HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to improved pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an HMG-CoA reductase inhibitor, and more particularly Fluvastatin, Atorvastatin or salts thereof in combination with a linear sulphated polysaccharide such as Carrageenan and a method for the preparation thereof. | 06-03-2010 |
| 20090062370 | Method for increasing the speed of recovery and/or the speed of wound healing of injured animals - This invention is in the field of animal food, in particular food for wounded animals. Surprisingly, it has now been found that the speed of recovery of wounded animals may be increased by feeding the animal with a certain amount of natural occurring immune enhancing ingredients such as beta-glucans and/or phytohormones like auxin or gibberellic acid. Also, combinations of these substances, in particular the combination of beta-glucans and phytohormones, were shown to have a synergistic effect in that they improved the recovery speed of the animal more than the individual components on their own. | 03-05-2009 |
| 20080287520 | Use of Melatonin in Preventing Postoperative Complications - The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture of a medicament for the therapeutic treatment, prophylactic treatment and/or prevention of postoperative infectious and/or non-infections complications induced by surgical interventions wherein the infectious complications may be pneumonia, wound infection (wound dehiscence), intra-abdominal abscess, and urinary tract infections (UTI) or wherein the non-infectious complication may be anastomotic leak, a pharmaceutical formulation comprising melatonin and at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof and a method for the therapeutic and/or prophylactic treatment of postoperative infectious and/or non-infectious complications induced by surgical interventions. | 11-20-2008 |
| 20080227846 | METHODS OF TREATING JUVENILE TYPE 1 DIABETES MELLITUS - The present disclosure describes methods for treating or preventing Type 1 diabetes mellitus in juveniles, particularly in juveniles newly diagnosed with Type 1 diabetes. This prevention or treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin, thereby decreasing the destruction of islet cells, or maintaining endogenous insulin production, in the juvenile. | 09-18-2008 |
| 20080306135 | Process for the Preparation of Crystalline Perindopril - The present invention relates to a new process for the preparation of crystalline perindopril. The present invention also relates to new alkyl ammonium salts of perindopril and the processes for the preparation thereof. | 12-11-2008 |
| 20080269312 | Inhibitors of Ccr9 Activity - N-(benzenesulphonyl)-2,3-dihydro-1H-indols, wherein the indol is substituted by cyano, carboxy or alkylcarbonyloxy and their use as therapeutical agents. | 10-30-2008 |
| 20080221199 | METHOD FOR IMPROVING MEMORY IN MAMMALS - A method for improving memory in healthy subjects is disclosed. This method makes use of melatonin receptor antagonists such as luzindole and/or K-185 to reverse the inhibitory effect of melatonin. This invention is particularly relevant among subjects that do not show signs of central nervous system disorders and wish to improve their cognitive performance, especially in tasks. | 09-11-2008 |
| 20080207731 | 3-(3-INDOLYL) PROPIONIC ACID CALCIUM SALT AND METHOD OF MAKING 3-(3-INDOLYL) PROPIONIC ACID FREE ACID THEREFROM - Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role. | 08-28-2008 |
| 20090264496 | Compounds, Compositions and Methods for Making the Same - The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A. | 10-22-2009 |
| 20100137401 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess. | 06-03-2010 |
| 20090163571 | PHARMACEUTICAL FOR USE IN THE TREATMENT OF URETEROLITHIASIS - The present invention provides pharmaceutical compositions useful for relieving pain caused by ureteral calculi, facilitating exclusion of ureteral calculi or the like. That is, the present invention provides a pharmaceutical composition for the treatment of ureteral lithiasis, which comprises as an active ingredient an indoline derivative represented by the following general formula (I) or a salt thereof. In the formula, R represents saturated or unsaturated aliphatic acyl which may have a substituent; hydroxyalkyl; aliphatic acyloxyalkyl; lower alkyl which has as a substituent lower alkoxy, carboxy, lower alkoxycarbonyl, aryl-substituted lower alkoxycarbonyl, carbamoyl, mono or di(lower alkyl)-substituted carbamoyl or cyano; optionally substituted aromatic acyl; furoyl or pyridylcarbonyl; R | 06-25-2009 |
| 20080319046 | SUBSTITUTED SULFONAMIDE-INDOLES - The present invention relates generally to substituted sulfonamide indoles such as substituted sulfonamide indoles, and methods of using them. | 12-25-2008 |
| 20080319045 | Combination of Histone Deacetylase Inhibitors and Radiation - This invention relates to organic compounds of formula (I): | 12-25-2008 |
| 20090186934 | Beta Crystalline form of the Arginine Salt of Perindopril, a Process for its Preparation and Pharmaceutical Compositions Containing it. - β-crystalline form of the compound of formula (I): | 07-23-2009 |
| 20090023797 | Indol-Alanine Derivatives as Selective S1P4-Agonists - The present invention relates to agonists of the S1P4 receptor, which are selective for the S1P4 receptor over one or more of the S1P1, S1P2, S1P3 or S1P5 receptors of at least 10 fold, in particular new indol-alanine derivatives of structure 1, process for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them | 01-22-2009 |
| 20090054511 | Tryptophan derivative and application thereof - It is intended to provide a tryptophan derivative that activates osteoblasts and to provide a therapeutic drug for osteoporosis and an osteoblast activator using this tryptophan derivative. | 02-26-2009 |
| 20090099248 | INHIBITORS OF D-AMINO ACID OXIDASE - The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia. | 04-16-2009 |
| 20120142750 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS - The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof. | 06-07-2012 |
| 20090209611 | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them - Provided are crystalline forms of fluvastatin sodium and processes for their preparation. | 08-20-2009 |
| 20080262072 | Compositions And Kits Comprising A Melatonin Component And A Flavanol Component - Disclosed herein are compositions and kits, wherein each composition comprises a melatonin component, a flavanol component, or both, and wherein each kit comprises a melatonin component and a flavanol component. The compositions and kits are useful for restorative sleep function and enhanced energy. Further disclosed herein are methods of using the compositions and kits. | 10-23-2008 |
| 20100184819 | METHOD FOR REDUCING INTRACRANIAL PRESSURE - The present invention relates generally to methods for reducing intracranial pressure in a subject. More particularly, the methods of the present invention include administering to the subject an effective amount of a substance P receptor antagonist. | 07-22-2010 |
| 20110060026 | Indoles Active on CRTH2 Receptor - Indole derivatives having therapeutic utility are of formula (I): X is —SO | 03-10-2011 |
| 20100197758 | ISCHEMIA/REPERFUSION PROTECTION COMPOSITIONS AND METHODS OF USING - The invention provides for ischemia/reperfusion protection compositions having one or more ketone bodies and melatonin. The invention also provides for methods of using such compositions to reduce or prevent ischemia/reperfusion injury due to blood loss, stroke or cardiopulmonary arrest or surgery. | 08-05-2010 |
| 20080214646 | Novel Nsaids Possessing a Nitric Oxide Donor Diazen-1-Ium-1,2-Diolate Moiety - This invention provides a prodrug that help arthritis patients without increasing cardiovascular and gastrointestinal risk. A novel group of hybrid nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs), moiety attached via a one -carbon methylene spacer to the carboxylic acid group of the traditional NSAIDs aspirin, ibuprofen and indomethacin were synthesized. The ester prodrugs showed equipotent anti-inflammatory activities in vivo to that of the parent aspirin, ibuprofen and indomethacin. The simultaneous release of parent drug and nitric oxide from the NO- prodrugs constitutes a potentially beneficial property for the prophylactic prevention of thrombus formation and adverse cardiovascular events such as stroke and myocardial infarction. Data acquired in an in vivo ulcer index (UI) assay showed that this group of ester prodrugs in which no lesions were observed when compared to the parent drugs at equivalent doses. Accordingly, these hybrid NO-NSAID prodrugs possessing a diazen-1-ium-1,2-diolate moiety, represents a new approach for the rational design of anti-inflammatory drugs with reduced gastric ulcerogenicity. | 09-04-2008 |
| 20100240727 | Model for Glutamate Racemase Inhibitors and Glutamate Racemase Antibacterial Agents - The increase in antibacterial resistance has created the demand for new antibiotics. The present invention relates to a more potent antibiotic that targets the enzyme glutamate racemase from known glutamate racemase inhibitors. Glutamate racemase catalyses the interconversion of L-glutamate to D-glutamate, making D-glutamate available, which is required for bacterial peptidoglycan biosynthesis. Knockout mutations have shown glutamate racemase to be necessary for bacterial cell survival and, before the present invention, no antibiotic on the market targeted this enzyme. The present invention relates to new, ligand based glutamate racemase inhibitors, developed using software to extract a pharmacophore model from a group of known glutamate racemase inhibitors. Forty-seven (47) known inhibitors were collected from the literature and several pharmacophore models were extracted therefrom. The functional groups common to all the known inhibitors were included in a pharmacophore model that described the requirements for glutamate racemase inhibition with 82% accuracy. Of these models, one was found to describe the requirements for glutamate racemase inhibition with 82% accuracy. The model was used to search databases of commercially available chemical compounds and 2-(2-(1H-indol-3-yl)ethylamino)-4-oxo-4-p-tolylbutanoic acid and 2-(2-(1H-indol-3-yl)ethylamino)-4-(4-fluorophenyl)-4-oxobutanoic acid were identified as showing antibacterial activity. These compounds were assayed against | 09-23-2010 |
| 20100099732 | MEDICAMENTS USEFUL AS POTASSIUM CHANNEL MODULATORS - This invention relates to pharmaceutical compositions comprising phenylcarbamoyl-methyl-indole derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels. | 04-22-2010 |
| 20120245213 | HUMAN TYPE I TASTE RECEPTOR SUBUNIT 3 MODULATORS AND METHODS OF USING SAME - Methods and compositions are provided for modulating the activity of human type I taste receptor subunit 3 (hT1R3). Such materials and methods are useful for the screening and preparation of compositions and methods for the treatment of carbohydrate and lipid metabolic diseases and disorders. | 09-27-2012 |
| 20090186935 | TASTE TITRATION THERAPIES - The teachings provided herein generally relate to formulations, systems, and methods that have the ability to remit deficiencies and imbalances in a subject's serotonin and dopamine levels. The teachings relate to the preparation and uses of a formulation comprising a serotonergic agent or dopaminergic agent in a form capable of oral transmucosal delivery to a subject. The formulation includes a flavoring agent and a carrier base. The flavoring agent functions as a taste indicator of the endpoint of a taste titration of the serotonergic or dopaminergic agent for a subject receiving an oral administration of the formulation in the form of a taste titration, and the endpoint is indicated to the subject by a change in the intensity of the flavor of the flavoring agent. | 07-23-2009 |
| 20080312308 | SUBSTITUTED ACETIC ACID DERIVATIVES - The present invention relates generally to substituted acetic acid derivatives and methods of using them. | 12-18-2008 |
| 20100305184 | INHIBITORS OF THE ATB(0,+) TRANSPORTER AND USES THEREOF - The present invention includes inhibitors of the amino acid transporter ATB | 12-02-2010 |
| 20100311805 | COMBINATION OF HISTONE DEACETYLASE INHIBITORS AND RADIATION - This invention relates to organic compounds of formula (I): | 12-09-2010 |
| 20110034531 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA - The invention relates to the use of an HDAC inhibitor, more specifically or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of melanoma; the use of an HDAC inhibitor or a pharmaceutically acceptable salt thereof in the treatment of melanoma; a method of treating warm-blooded animals including mammals, especially humans, suffering from melanoma by administering to a said animal in need of such treatment a dose effective against said disease of an HDAC inhibitor or a pharmaceutically acceptable salt thereof. | 02-10-2011 |
| 20110245316 | PREVENTION OR DELAY OF ONSET OF ORAL MUCOSITIS - The present invention provides a method for preventing or delaying the onset of oral mucositis, including the onset of ulcerative or severe OM, in a patient receiving cancer therapy. The method comprises administering to the patient an effective regimen of γ-D-glutamyl-L-tryptophan (SCV-07) over the course of therapy. The regimen, which includes scheduled doses of SCV-07 with respect to radiation exposure and/or chemotherapy, is effective for preventing or delaying the onset of OM. In accordance with the invention, the patient is more able to complete the planned course of cancer therapy (including chemotherapy and/or radiation therapy), by maintaining a sufficient nutritional state, and by avoiding the significant pain and discomfort associated with OM. | 10-06-2011 |
| 20110178150 | Use of Indole Derivatives as NURR-1 Activators for Treating Parkinson's Disease - The present invention relates to a compound derived from indole, especially a therapeutically useful compound, characterized in that it is selected from compounds of formula (I) | 07-21-2011 |
| 20100305183 | METHOD AND COMPOSITION FOR REDUCING REPERFUSION INJURY - The present invention relates to a method of preventing and/or reducing reperfusion injury to a tissue, organ, or organ system in a subject. The method includes administering to the subject an effective amount of a substance P receptor antagonist. | 12-02-2010 |
| 20080249155 | 5-Hydroxyindole-3-Carboxylate Derivatives and Uses Thereof - The present invention relates to 5-hydroxy-indole-3-carboxylate derivatives of formula I, or racemic mixture or optical isomers or pharmaceutically acceptable salts and/or hydrates thereof, | 10-09-2008 |
| 20090318528 | HYDRATE CRYSTALS - New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal are useful as sweeteners and for the preparation of orally consumed products, such as foods, beverages, pharmaceutical products, topical pharmaceutical products, and feeds containing general-purpose, stable, and safe monatin sodium salt crystals. | 12-24-2009 |
| 20080221197 | INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS - The present invention provides indole compounds of Formula (I) or (II): | 09-11-2008 |
| 20090118351 | Angiotensin I-Converting Enzyme (ACE) Inhibitors - This invention relates to a process for synthesising an amino acid derivative of a tripeptidomimetic, such as lisinopril. The invention also relates to a derivative of lisinopril, incorporating a amino acid moeity such as tryptophan at the P2′ position. | 05-07-2009 |
| 20080214647 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) - This invention provides compounds of the formula: | 09-04-2008 |
| 20080200532 | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them - Provided are polymorphic forms of fluvastatin sodium and processes for their preparation. | 08-21-2008 |
| 20110257239 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION AND METHOD OF RELEASING PHARMACEUTICALLY ACTIVE AGENT - The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amounts of a pharmaceutically active agent, hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected froth the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000. | 10-20-2011 |
| 20110118327 | IN VIVO ASSESSMENT OF TOXICITY AND PHARMACOKINETICS OF METHYLGLYOXAL - A pharmaceutical composition and treatment method to reduce the proliferation of cancerous or tumor cells, in which the combined active agents are methylglyoxal, ascorbic acid, creatine and melatonin. | 05-19-2011 |
| 20100324109 | Composition for Topical Use - The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. | 12-23-2010 |
| 20110218227 | HYDRATE CRYSTALS - New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal are useful as sweeteners and for the preparation of orally consumed products, such as foods, beverages, pharmaceutical products, topical pharmaceutical products, and feeds containing general-purpose, stable, and safe monatin sodium salt crystals. | 09-08-2011 |
| 20090326037 | Medicinal Agent For Treating Viral Infections - The invention relates to medicine, in particular to searching and developing novel medicinal agents for treating and preventing viral infections, mainly influenza viruses. The aim of said invention is to develop more efficient and low toxic medicinal agents by combining arbidol and the analogs thereof with a preparation exhibiting another mechanism of action. Said combinations enhances the efficiency of the preparation small doses and makes it possible to reduce the probability of side effects and appearance of virus resistant strain by reducing the dose. The result is attained by the combined use of arbidol and the analogies thereof with at least one type of preparation selected from the following group of antiviral preparations: ribavirin, zanamivirin, oseltavirin, peramirin, amantadin or remantadin. | 12-31-2009 |
| 20090281160 | Angiotensin I-converting enzyme (ace) inhibitors - This invention relates to a process for the synthesis of ketomethylene derivatives of the tripeptide Phe-Gly-Pro (“keto-ACE”, compound 5 | 11-12-2009 |
| 20100029742 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN - The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F), the crystal modification 2 (polymorphic form I), and the crystal modification 3 (polymorphic form X) of the mono-sodium salt of D-isoglutamyl-D-tryptophan. | 02-04-2010 |
| 20110313014 | PRODUCTS COMPRISING N-PHENYLPROPENOYL AMINO ACID AMIDES AND USES THEREOF - The present invention relates to use of a composition comprising N-phenylpropenoyl amino acid amides for the preparation of a product to treat or prevent neurodegenerative disorders, cognitive decline, mild cognitive impairment, dementia, mood disorders, depression, sleep disorders, diseases involving protein aggregation in a human or animal, Alzheimer's disease, macular degeneration or diabetes. The invention further relates to products comprising N-phenylpropenoyl amino acid amides, including food and beverage products, food supplements, and pet food products, and methods for affecting cognitive performance of humans and animals. | 12-22-2011 |
| 20090312391 | UNIFYING MECHANISM AND METHODS TO PREVENT CANCER AND NEURODEGENERATIVE DISEASES - The present invention relates to methods for preventing the development of cancer or neurodegenerative diseases by administering N-Acetylcysteine (NAC), melatonin, or a combination thereof. The present invention also relates to methods for diagnosing cancer and/or neurdegenerative disease by detecting or determining the amount of dopamine metabolites, 4-CE, 2-CE, methylation of CE or CE-Q conjugates. | 12-17-2009 |
| 20120010263 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY - The invention provides compounds of formula I | 01-12-2012 |
| 20120016000 | METHOD TO ASSAY PHOSPHOLIPID AND TRIGLYCERIDE TRANSFER ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN - The present invention is directed to a method for identifying an antagonist compound of microsomal triglyceride transfer protein (MTP), wherein the antagonist at least partially inhibits triglyceride transfer activity while not significantly inhibiting phospholipids transfer activity of MTP. In particular, the present invention is directed to assays for phospholipid (PL) and triglyceride (TG) transfer activity having considerably improved sensitivity. In addition, antagonist compounds that modulate the lipid transfer activity of MTP are provided. Kits for measuring the lipid transfer activity of MTP are also provided by the present invention. | 01-19-2012 |
| 20090023798 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE - Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase. Also described herein are methods of using such HDAC inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC activity. | 01-22-2009 |
| 20080293801 | Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity - A composition comprises a solid amorphous dispersion comprising (S)—N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-methyl-5-[4′-(trifluoromethyl)[1,1′-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide and a polymer. | 11-27-2008 |
| 20090197936 | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PH- ENYL]-2E-2-PROPENAMIDE - Salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide are prepared and characterized. | 08-06-2009 |
| 20100317710 | 3-(3-INDOLYL) PROPIONIC ACID CALCIUM SALT AND METHOD OF MAKING 3-(3-INDOLYL) PROPIONIC ACID FREE ACID THEREFROM - Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role. | 12-16-2010 |
| 20120095071 | 3-(3-INDOLYL) PROPIONIC ACID CALCIUM SALT AND METHOD OF MAKING 3-(3-INDOLYL) PROPIONIC ACID FREE ACID THEREFROM - Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium can be used to inhibit the cytotoxic effects of amyloid beta protein on cells, to treat fibrillogenic diseases in a mammal, and to treat diseases or conditions in which free radicals or oxidative stress plays a role. | 04-19-2012 |
| 20100204295 | TREATMENT OF ALLERGIC DISEASE WITH IMMUNOMODULATOR COMPOUNDS - A method of treatment for treating, preventing, inhibiting or reducing allergic disease or its effects in a subject, comprises administering to the subject an effective amount of an immunomodulator compound, which composes an aromatic or heterocyclic amino acid residue or a derivative thereof. Preferably, the immunomodulatory compound is a dipeptide which comprises a D- or L-tryptophan residue. | 08-12-2010 |
| 20120283308 | ANIMAL FEED COMPOSITION - Disclosed is an animal feed composition that comprises free indole acetic acid (free IAA) or a derivative thereof. Also disclosed is a method for enhancing animal growth by feeding the animal with a composition according to the invention. Further disclosed is the use of free IAA or a derivative thereof in a method of therapy of animals in need of a growth-promoting treatment, such as immunocompromised animals, animals with a growth deficit or slow-growing animals. Disclosed is the use of free IAA or a derivative thereof for the preparation of a therapeutical composition for increasing the growth rate and/or the feed conversion rate and/or the immunity of animals in need of such a treatment, in particular, immunocompromised or slow-growing animals. A composition may be in the form of a food or feed supplement. | 11-08-2012 |
| 20120149752 | KIT FOR BALANCING NEUROTRANSMITTER LEVELS - The teachings provided herein generally relate to formulations, systems, and methods that have the ability to remit deficiencies and imbalances in a subject's serotonin and dopamine levels. The teachings relate to the preparation and uses of a formulation comprising a serotonergic agent or dopaminergic agent in a form capable of oral transmucosal delivery to a subject. The formulation includes a flavoring agent and a carrier base. The flavoring agent functions as a taste indicator of the endpoint of a taste titration of the serotonergic or dopaminergic agent for a subject receiving an oral administration of the formulation in the form of a taste titration, and the endpoint is indicated to the subject by a change in the intensity of the flavor of the flavoring agent. | 06-14-2012 |
| 514420000 | Indomethacine per se or ester thereof | 9 |
| 20100063128 | Indole compounds, a process for their preparation and pharmaceutical compositions containing them. - Compounds of formula (I): | 03-11-2010 |
| 20130065934 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES - The invention relates to fatty acid COX inhibitor derivatives; compositions comprising an effective amount of a fatty acid COX inhibitor derivative; and methods for treating or preventing a metabolic, autoimmune, inflammatory, or neurodegenerative disorder comprising the administration of an effective amount of a fatty acid COX inhibitor derivative. | 03-14-2013 |
| 20110294864 | AQUEOUS COACERVATE COMPOSITIONS SUITABLE FOR MAKING POWDERS AND WATER-SOLUBLE FORMULATIONS OF BIOLOGICALLY-ACTIVE AGENTS - Aqueous gel-free two-phase coacervate compositions including a coacervate phase and an equilibrium water phase, comprising a mixture of:
| 12-01-2011 |
| 20080293804 | Pharmaceutical Nasal Spray Formulation of Acetaminophen (paracetamol) - The invention in question is a novel pharmaceutical formulation that comprises a one percent weight by volume Paracetamol in a phosphate buffer adjusted to pH 7.4 by addition of few drops of 1.0 N NaOH. The concentrations of the ingredients were chosen such that the resulting solution is isotonic with body fluids. Said concentrations were theoretically calculated based on their sodium chloride equivalents. The formulation is meant to be used as a nasal spray. | 11-27-2008 |
| 20090137656 | Intermolecular Association Complex of a Carrier and of an Active Principle - The invention relates to an intermolecular association complex of formula (I) of an amphiphilic carrier and of an active principle Z-Y, in which; S, X n, R | 05-28-2009 |
| 20090137657 | EXTERNAL LIQUID PREPARATION CONTAINING INDOMETHACIN - The present invention provides an indomethacin-containing external liquid preparation which provides good feeling of use, which exhibits high percutaneous absorption of indomethacin, and which, particularly in a low-temperature environment, does not cause precipitation of crystals with time. | 05-28-2009 |
| 20100152272 | FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM - Compounds selected from: | 06-17-2010 |
| 20100022614 | PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION AND ADHESIVE SKIN PATCH - Disclosed are a pharmaceutical composition for external application, an adhesive skin patch and others which are improved in a drug release property, transdermal absorbability and stability of a pharmacologically active ingredient contained therein and can reduce the aggravation of irritation to the skin. Specifically disclosed is an adhesive skin patch comprising a support and an adhesive layer laminated on the support, wherein the adhesive layer contains a pharmaceutical composition for external application. The pharmaceutical composition for external application comprises a pharmacologically active ingredient, an auxiliary component and a pyrrolidone compound, wherein one of the pharmacologically active ingredient and the auxiliary component has a carboxylate group in the molecule and the other has a hydroxy group in the molecule. Preferably, the adhesive layer further comprises a hydrogenated oil. | 01-28-2010 |
| 20120178788 | METHOD FOR SUPPRESSING ESTERIFICATION OF PHARMACEUTICAL COMPOSITION - Disclosed are a pharmaceutical composition for external application, an adhesive skin patch and others which are improved in a drug release property, transdermal absorbability and stability of a pharmacologically active ingredient contained therein and can reduce the aggravation of irritation to the skin. Specifically disclosed is an adhesive skin patch comprising a support and an adhesive layer laminated on the support, wherein the adhesive layer contains a pharmaceutical composition for external application. The pharmaceutical composition for external application comprises a pharmacologically active ingredient, an auxiliary component and a pyrrolidone compound, wherein one of the pharmacologically active ingredient and the auxiliary component has a carboxylate group in the molecule and the other has a hydroxy group in the molecule. Preferably, the adhesive layer further comprises a hydrogenated oil. | 07-12-2012 |
